You had searched for:

There were no results matching the query.

You can also browse the topics below to find what you are looking for.

Support Services

  1. Download the Prescription and Service Request Form (PSRF)
  2. Fax the completed form to Shared Solutions® at 1-844-257-6127

Patients can call 1-800-887-8100, Monday–Friday, 8 am–6 pm CT.

Help patients say yes to more moments

  • HALO: AJOVY may give your patients more migraine-free days vs placebo.1

    Select the data:

  • HALO: AJOVY may help patients reduce migraine by 50% or more.1

    Select the data:

  • FOCUS: AJOVY was studied in patients with an inadequate response to 2 or more classes of prior preventive treatments.2

HALO: With AJOVY, patients experienced significantly more migraine-free days vs placebo1

In chronic migraine, a reduction in monthly headache days of at least moderate severity was demonstrated during the 12-week period (primary endpoint), with results seen as early as week 11,2

Chronic Migraine

REDUCTION IN MONTHLY HEADACHE DAYS OF AT LEAST MODERATE SEVERITY (PRIMARY ENDPOINT)1,2

Line chart describing clinical trial data of chronic migraine patients receiving AJOVY over the 12-week period

In episodic migraine, a reduction in monthly migraine days was demonstrated during the 12-week period (primary endpoint), with results seen as early as week 11,2

Episodic Migraine

REDUCTION IN MONTHLY MIGRAINE DAYS (PRIMARY ENDPOINT)1,2

Line chart describing clinical trial data of episodic migraine patients receiving AJOVY over the 12-week period

Patients with chronic and episodic migraine receiving AJOVY had a significant reduction in the use of acute medication vs placebo (secondary endpoint)1,2‡

 

Reduction of acute medication use (secondary endpoint): Patients in the chronic migraine trial with a mean baseline of 13.1 days for both monthly and quarterly dosing and 13.0 days for placebo saw a mean reduction of: 4.2 days for monthly dosing, 3.7 days for quarterly dosing vs 1.9 days with placebo, P<0.001. Patients in the episodic migraine trial with a mean baseline of 7.7 days for monthly dosing, 7.8 days for quarterly dosing, and 7.7 days for placebo saw a mean reduction of: 3.0 days for monthly dosing, 2.9 days for quarterly dosing vs 1.6 days with placebo, P<0.001.1,2

SEE HALO STUDY DESIGNS

HALO: AJOVY reduced migraine days by 50% or more1

Chronic Migraine

PATIENTS ACHIEVING AT LEAST A 50% REDUCTION IN MONTHLY AVERAGE HEADACHE DAYS OF AT LEAST MODERATE SEVERITY (SECONDARY ENDPOINT)1

Bar chart describing clinical trial data of chronic migraine patients receiving AJOVY with monthly dosing

1 in 5 patients with chronic migraine experienced a 75% reduction in monthly average headache days vs 1 in 10 with placebo (post hoc analysis)2

Episodic Migraine

PATIENTS ACHIEVING AT LEAST A 50% REDUCTION IN MONTHLY AVERAGE MIGRAINE DAYS (SECONDARY ENDPOINT)1

 Bar chart describing clinical trial data of episodic migraine patients receiving AJOVY with monthly dosing

1 in 4 patients with episodic migraine experienced a 75% reduction in monthly average migraine days vs ~1 in 7 with placebo (post hoc analysis)2

 

For all post hoc analyses, no determination of statistical significance can be made and no conclusions should be drawn.

SEE HALO STUDY DESIGNS

FOCUS
was the largest study of its kind (N=838) in patients with inadequate response to 2 or more classes of prior preventive treatments3

Phase 3b, multicenter, randomized, double-blind, parallel group, placebo-controlled study, evaluating efficacy and safety of quarterly and monthly treatment with AJOVY, compared to placebo in patients with chronic or episodic migraine who had experienced inadequate response* to 2 to 4 classes of prior preventive treatments

*Inadequate response to a prior medication was defined as: (1) no clinically meaningful improvement after at least 3 months (2) patient could not tolerate the drug (3) drug was contraindicated for patient or (4) drug was not suitable for the patient.3

FOCUS: Significant reduction in average monthly migraine days compared to placebo after inadequate response to 2 or more classes of preventive treatments (primary endpoint)3

Change from baseline in average monthly mIgraine days during the focus phase 3b study3

Bar chart describing the clinical data from the FOCUS trial, change from baseline in average monthly migraine days with quarterly or monthly dosing of AJOVY vs placebo

FOCUS: Patients who achieved ≥50% reduction in monthly average migraine days3

Percentage of patients achieving ≥50% reduction in average monthly migraine days vs placebo during the 12-week study period (secondary endpoint)3

Bar chart describing the clinical data from the FOCUS trial, patients achieving a greater than or equal to 50% reduction with quarterly or monthly dosing of AJOVY vs placebo

Suggestions to explore next

Continue to AJOVY Dosing Flexibility page

Flexibility to help you meet your patients' needs1

Dosing Options for AJOVY
Continue to AJOVY Clinical Trial Designs page

AJOVY was studied in two phase 3 clinical trials1

See Study designs
Continue to AJOVY Patient Support page

Savings Offer coupon for AJOVY

Learn how much AJOVY may cost eligible patients